Metabolic syndrome (MetS) and cardiovascular diseases (CVDs) rank among the top morbidity and mortality burdens globally. The pathogenetic processes underlying the clustering of these conditions in affected individuals likely represent intricate interplays between environmental/lifestyle factors and the body’s response to pathophysiological stimuli. The adrenal neuroendocrine system plays important role in the body’s response to physical and psychological stress, in the regulation of energy and substrate metabolism, fluid and electrolyte balance, cardiovascular tissue remodeling, and immune function, thereby underscoring cardiometabolic health. MetS and CVDs are common features in people exposed to excess glucocorticoids, mineralocorticoids, and disturbances in sympatho-adrenergic responses. Emerging evidence suggests that therapeutic targeting of the adrenal neuroendocrine system may have protective cardiometabolic effects, but the crucial targets and clinical significance are yet to be established.
This Research Topic aims to feature the advances in the literature on the role of the adrenal neuroendocrine system in the regulation of cardiovascular and metabolic health and its clinical implications.
We welcome manuscripts (original research, literature review) reporting the latest research encompassing but not limited to the following themes:
- Cardiometabolic complications of excess glucocorticoids/ mineralocorticoids/disturbance in sympatho-adrenergic system – pathophysiology, management;
- Role of mineralocorticoids, aldosterone and the mineralocorticoid receptor in cardiometabolic health;
- Role of glucocorticoid signaling in cardiovascular and metabolic homeostasis;
- Interplay between the glucocorticoid and mineralocorticoid systems in various cells, tissues, and organs such as immune cells, adipose tissue, cardiac and vascular tissue affecting cardiovascular and metabolic health;
- Stress and cardiometabolic health – role of sympathetic and hypothalamic-pituitary-adrenal axis responsiveness;
- Therapeutic advances targeting the adrenal neuroendocrine system for cardiometabolic health;
Metabolic syndrome (MetS) and cardiovascular diseases (CVDs) rank among the top morbidity and mortality burdens globally. The pathogenetic processes underlying the clustering of these conditions in affected individuals likely represent intricate interplays between environmental/lifestyle factors and the body’s response to pathophysiological stimuli. The adrenal neuroendocrine system plays important role in the body’s response to physical and psychological stress, in the regulation of energy and substrate metabolism, fluid and electrolyte balance, cardiovascular tissue remodeling, and immune function, thereby underscoring cardiometabolic health. MetS and CVDs are common features in people exposed to excess glucocorticoids, mineralocorticoids, and disturbances in sympatho-adrenergic responses. Emerging evidence suggests that therapeutic targeting of the adrenal neuroendocrine system may have protective cardiometabolic effects, but the crucial targets and clinical significance are yet to be established.
This Research Topic aims to feature the advances in the literature on the role of the adrenal neuroendocrine system in the regulation of cardiovascular and metabolic health and its clinical implications.
We welcome manuscripts (original research, literature review) reporting the latest research encompassing but not limited to the following themes:
- Cardiometabolic complications of excess glucocorticoids/ mineralocorticoids/disturbance in sympatho-adrenergic system – pathophysiology, management;
- Role of mineralocorticoids, aldosterone and the mineralocorticoid receptor in cardiometabolic health;
- Role of glucocorticoid signaling in cardiovascular and metabolic homeostasis;
- Interplay between the glucocorticoid and mineralocorticoid systems in various cells, tissues, and organs such as immune cells, adipose tissue, cardiac and vascular tissue affecting cardiovascular and metabolic health;
- Stress and cardiometabolic health – role of sympathetic and hypothalamic-pituitary-adrenal axis responsiveness;
- Therapeutic advances targeting the adrenal neuroendocrine system for cardiometabolic health;
